Phoenix Financial Ltd. Purchases 6,332 Shares of Johnson & Johnson $JNJ

Phoenix Financial Ltd. increased its position in Johnson & Johnson (NYSE:JNJ) by 13.5% during the third quarter, Holdings Channel reports. The fund owned 53,162 shares of the company’s stock after purchasing an additional 6,332 shares during the quarter. Phoenix Financial Ltd.’s holdings in Johnson & Johnson were worth $13,804,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently bought and sold shares of JNJ. Outlook Capital Management LLC bought a new position in Johnson & Johnson in the 2nd quarter worth about $28,000. Matrix Trust Co increased its stake in shares of Johnson & Johnson by 56.2% in the second quarter. Matrix Trust Co now owns 150 shares of the company’s stock valued at $38,000 after purchasing an additional 54 shares during the period. Navigoe LLC increased its stake in shares of Johnson & Johnson by 60.4% in the third quarter. Navigoe LLC now owns 146 shares of the company’s stock valued at $38,000 after purchasing an additional 55 shares during the period. Montgomery Financial Services LLC bought a new stake in shares of Johnson & Johnson during the second quarter valued at approximately $43,000. Finally, Hanseatic Management Services Inc. bought a new stake in shares of Johnson & Johnson during the third quarter valued at approximately $52,000. 69.55% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Elizabeth Forminard sold 13,072 shares of the stock in a transaction on Thursday, November 12th. The stock was sold at an average price of $284.39, for a total transaction of $3,717,546.08. Following the completion of the transaction, the executive vice president directly owned 16,994 shares of the company’s stock, valued at approximately $4,832,923.66. This trade represents a 43.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Jennifer Taubert sold 15,000 shares of Johnson & Johnson stock in a transaction on Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the transaction, the executive vice president owned 194,451 shares in the company, valued at approximately $51,210,615.36. This trade represents a 7.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 61,669 shares of company stock valued at $16,898,386. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ traded up $2.26 during trading on Friday, reaching $285.78. The company had a trading volume of 6,279,519 shares, compared to its average volume of 7,472,752. The firm’s fifty day moving average is $266.97 and its 200 day moving average is $249.85. The firm has a market capitalization of $687.95 billion, a PE ratio of 43.30, a price-to-earnings-growth ratio of 2.80 and a beta of 0.22. Johnson & Johnson has a twelve month low of $193.55 and a twelve month high of $288.11. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The business had revenue of $25.40 billion during the quarter, compared to analysts’ expectations of $25.38 billion. During the same period last year, the firm posted $2.80 earnings per share. The business’s revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, equities analysts forecast that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be given a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio is 81.21%.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of recent analyst reports. Bank of America reissued a “neutral” rating and issued a $278.00 price objective on shares of Johnson & Johnson in a report on Tuesday, September 29th. Evercore set a $300.00 target price on Johnson & Johnson in a research report on Tuesday, October 20th. TD Cowen reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, October 20th. Wells Fargo & Company boosted their price target on Johnson & Johnson from $275.00 to $287.00 and gave the stock an “overweight” rating in a research report on Friday, October 16th. Finally, HSBC raised their price target on Johnson & Johnson from $290.00 to $320.00 and gave the company a “buy” rating in a report on Thursday, September 10th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $275.92.

Johnson & Johnson News Summary

Here’s some of the latest news about JNJ:

• Positive Sentiment: A Johnson & Johnson prostate-cancer drug combination is advancing into Phase 3, a meaningful clinical milestone that could strengthen the company’s oncology pipeline, although trial and commercial outcomes remain uncertain. Johnson & Johnson stock advances as prostate drug combo enters Phase 3
• Positive Sentiment: J&J is backing Francis Medical as it advances a water-vapor prostate-cancer treatment device toward FDA premarket approval. The investment expands its reach in minimally invasive oncology treatment. J&J leads Francis Medical investment to fund prostate cancer device
• Positive Sentiment: JNJ has risen 10.4% since its latest earnings report, and State Street’s Health Care SPDR added shares on Nov. 10. These reports suggest continued investor interest, though neither guarantees further gains. Johnson & Johnson Up 10.4% Since Last Earnings Report State Street Health Care SPDR Adds Johnson & Johnson

About Johnson & Johnson

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.